{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT04723394_TACKLE\\NCT04723394_TACKLE_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "All participants analysis set",
        "text": "All participants screened for the study, to be used for reporting disposition and screening failures.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "PAS",
        "populationDescription": "All participants screened for the study, to be used for reporting disposition and screening failures.",
        "criteria": "All screened participants"
      },
      {
        "id": "pop_2",
        "name": "Full analysis set",
        "text": "All randomized participants who received IMP, irrespective of their protocol adherence and continued participation in the study. Participants will be analyzed according to their randomized treatment, irrespective of whether or not they have prematurely discontinued, according to the intent-to-treat principle. Participants who withdraw consent or assent to participate in the study will be included up to the date of their study termination.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "All randomized participants who received IMP, irrespective of their protocol adherence and continued participation in the study. Participants will be analyzed according to their randomized treatment, irrespective of whether or not they have prematurely discontinued, according to the intent-to-treat principle. Participants who withdraw consent or assent to participate in the study will be included up to the date of their study termination.",
        "criteria": "Randomized AND received IMP"
      },
      {
        "id": "pop_3",
        "name": "Modified full analysis set",
        "text": "All participants in the full analysis set who received IMP ≤ 7 days from symptom onset and were not hospitalized at baseline (≤ Day 1) for isolation purpose.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "mFAS",
        "populationDescription": "All participants in the full analysis set who received IMP ≤ 7 days from symptom onset and were not hospitalized at baseline (≤ Day 1) for isolation purpose.",
        "criteria": "In FAS AND received IMP <= 7 days from symptom onset AND not hospitalized at baseline for isolation"
      },
      {
        "id": "pop_4",
        "name": "Early Intervention Analysis Set",
        "text": "All participants in the modified full analysis set who received IMP ≤ 5 days from symptom onset.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "EIAS",
        "populationDescription": "All participants in the modified full analysis set who received IMP ≤ 5 days from symptom onset.",
        "criteria": "In mFAS AND received IMP <= 5 days from symptom onset"
      },
      {
        "id": "pop_5",
        "name": "Seronegative Analysis Set",
        "text": "All participants in the modified full analysis set who were seronegative at baseline.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "SAS_Sero",
        "populationDescription": "All participants in the modified full analysis set who were seronegative at baseline.",
        "criteria": "In mFAS AND seronegative at baseline"
      },
      {
        "id": "pop_6",
        "name": "Safety analysis set",
        "text": "The safety analysis set consists of all participants who have received IMP. Erroneously-treated participants (eg, those randomized to treatment A, but were actually given treatment B) are accounted for in this analysis set by assigning them to the treatment they actually received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The safety analysis set consists of all participants who have received IMP. Erroneously-treated participants (eg, those randomized to treatment A, but were actually given treatment B) are accounted for in this analysis set by assigning them to the treatment they actually received.",
        "criteria": "Received IMP"
      },
      {
        "id": "pop_7",
        "name": "PK analysis set",
        "text": "Dosed participants for whom an adequate (measurable drug concentration) PK profile has been obtained. All participants who received AZD7442 and from whom PK blood samples are assumed not to be affected by factors such as protocol violations, and who had at least one quantifiable serum PK observation post dose, will be included in the PK analysis dataset.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PKAS",
        "populationDescription": "Dosed participants for whom an adequate (measurable drug concentration) PK profile has been obtained. All participants who received AZD7442 and from whom PK blood samples are assumed not to be affected by factors such as protocol violations, and who had at least one quantifiable serum PK observation post dose, will be included in the PK analysis dataset.",
        "criteria": "Received AZD7442 AND evaluable PK profile AND >=1 quantifiable post-dose PK observation"
      },
      {
        "id": "pop_8",
        "name": "Virology analysis set",
        "text": "The Virology analysis set consists of all participants in Cohort 1, who undergo more intensive virologic and immunologic assessments. Participants will be analyzed according to their received treatment.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "VAS",
        "populationDescription": "The Virology analysis set consists of all participants in Cohort 1, who undergo more intensive virologic and immunologic assessments. Participants will be analyzed according to their received treatment.",
        "criteria": "In Cohort 1"
      },
      {
        "id": "pop_9",
        "name": "ADA evaluable analysis set",
        "text": "The ADA evaluable analysis set contains all participants in the Safety analysis set who have a non-missing baseline AZD7442 ADA result and at least one non-missing post-baseline AZD7442 ADA result.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "ADA",
        "populationDescription": "The ADA evaluable analysis set contains all participants in the Safety analysis set who have a non-missing baseline AZD7442 ADA result and at least one non-missing post-baseline AZD7442 ADA result.",
        "criteria": "In Safety Set AND non-missing baseline ADA result AND >=1 non-missing post-baseline ADA result"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age of participant in years"
      },
      {
        "id": "char_2",
        "name": "Time from symptom onset",
        "code": "TIME_FROM_SYMPTOM_ON",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Time from symptom onset",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Stratification factor: <= 5 days versus > 5 days"
      },
      {
        "id": "char_3",
        "name": "Risk of progression",
        "code": "RISK_OF_PROGRESSION",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Risk of progression",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Stratification factor: High risk versus low risk of progression to severe COVID-19"
      },
      {
        "id": "char_4",
        "name": "BMI",
        "code": "BMI",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "BMI",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Body Mass Index"
      },
      {
        "id": "char_5",
        "name": "Smoking History",
        "code": "SMOKING_HISTORY",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Smoking History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "History of smoking"
      }
    ],
    "summary": {
      "populationCount": 9,
      "characteristicCount": 5
    }
  }
}